Sameem Abedin, MD

Articles by Sameem Abedin, MD

Harry Erba, MD, PhD, an expert on leukemia

Acute Myeloid Leukemia: Updates From The ASH 2022 Annual Meeting

BySameem Abedin, MD,Elias Jabbour, MD,Harry Erba, MD, PhD,Anjali Advani, MD

February 14th 2023

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

Anjali Advani, MD, an expert on leukemia

ASH 2022: Recent Advances in Chronic Myeloid Leukemia

BySameem Abedin, MD,Elias Jabbour, MD,Harry Erba, MD, PhD,Anjali Advani, MD

February 14th 2023

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

Elias Jabbour, MD, an expert on leukemia

ASH 2022: Updates in the Acute Lymphocytic Leukemia Treatment Landscape

BySameem Abedin, MD,Elias Jabbour, MD,Harry Erba, MD, PhD,Anjali Advani, MD

February 14th 2023

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

Dr. Abedin on the Safety and Efficacy of Ibrutinib in CLL

BySameem Abedin, MD

July 6th 2021

Sameem Abedin, MD, discusses the safety and efficacy of ibrutinib in the treatment of patients with chronic lymphocytic leukemia.

Dr. Abedin on Managing Cardiac Toxicities With Acalabrutinib vs Ibrutinib in CLL

BySameem Abedin, MD

June 22nd 2021

Sameem Abedin, MD, discusses managing cardiac toxicities with acalabrutinib vs ibrutinib in patients with chronic lymphocytic leukemia.

Dr. Abedin on Frontline Treatment Considerations in CLL 

BySameem Abedin, MD

June 21st 2021

Sameem Abedin, MD, discusses frontline treatment considerations for patients with chronic lymphocytic leukemia.

Sameem Abedin, MD, of the Medical College of Wisconsin

Dr. Abedin on the Clinical Significance of Undetectable MRD in CLL

BySameem Abedin, MD

June 21st 2021

Sameem Abedin, MD, discusses the clinical significance of undetectable minimal residual disease status in chronic lymphocytic leukemia.

Dr. Abedin on the Need for Risk Stratification Before Chemoimmunotherapy in CLL

BySameem Abedin, MD

June 3rd 2021

Sameem Abedin, MD, discusses the need for risk stratification prior to giving chemoimmunotherapy to patients with chronic lymphocytic leukemia.

Dr. Abedin on PI3K Inhibitors in CLL

BySameem Abedin, MD

August 12th 2019

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the use of PI3K inhibitors in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Abedin on the Role of Venetoclax Plus Obinutuzumab in CLL

BySameem Abedin, MD

June 4th 2019

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the role of venetoclax plus obinutuzumab in chronic lymphocytic leukemia.

Dr. Abedin Discusses Key Updates in CLL

BySameem Abedin, MD

May 2nd 2019

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses key updates in the treatment of patients with chronic lymphocytic leukemia.